Glial fibrillary acidic protein (GFAP) is the major intermediate filament protein in astrocytes, one of the most abundant cell types in the vertebrate central nervous system (CNS). Transcriptional regulation of GFAP is of interest because of its astrocyte-specificity and its upregulation during development and CNS injury. A 2.2 kb human GFAP promoter, gfa2, has been found to express in astrocytes throughout the CNS. In contrast, we recently found that the 448 bp gfa28 promoter expresses in only restricted CNS regions, and is active in neurons as well as astrocytes. In the present study we have used transgenic mice to investigate which DNA regions deleted from gfa2 in the formation of gfa28 are responsible for these differences. We have found that a 55 bp segment spanning bp -1488 to -1434 with respect to the RNA start site contains region-specific elements and that a 45 bp sequence spanning bp -1443 to -1399 is required for silencing expression in neurons. These data also further confirm the heterogeneity of astrocytes and neurons in the activation and repression of the GFAP gene, respectively. These studies also generated a novel 681 bp GFAP promoter, gfaABC(1)D, that has essentially the same expression pattern as the 2210 bp gfa2 promoter, and about twofold greater activity, recommending it for gene targeting applications in which size matters. In addition, a 681 bp gfaABC(1)(mC(1.1))D variant was generated that could limit expression of transgenes to astrocytes in the dorsal and caudal cortex, hippocampus and caudal vermis of the cerebellum.

Here, we describe the early events in the disease pathogenesis of Alexander disease. This is a rare and usually fatal neurodegenerative disorder whose pathological hallmark is the abundance of protein aggregates in astrocytes. These aggregates, termed "Rosenthal fibers," contain the protein chaperones alpha B-crystallin and HSP27 as well as glial fibrillary acidic protein (GFAP), an intermediate filament (IF) protein found almost exclusively in astrocytes. Heterozygous, missense GFAP mutations that usually arise spontaneously during spermatogenesis have recently been found in the majority of patients with Alexander disease. In this study, we show that one of the more frequently observed mutations, R416W, significantly perturbs in vitro filament assembly. The filamentous structures formed resemble assembly intermediates but aggregate more strongly. Consistent with the heterozygosity of the mutation, this effect is dominant over wild-type GFAP in coassembly experiments. Transient transfection studies demonstrate that R416W GFAP induces the formation of GFAP-containing cytoplasmic aggregates in a wide range of different cell types, including astrocytes. The aggregates have several important features in common with Rosenthal fibers, including the association of alpha B-crystallin and HSP27. This association occurs simultaneously with the formation of protein aggregates containing R416W GFAP and is also specific, since HSP70 does not partition with them. Monoclonal antibodies specific for R416W GFAP reveal, for the first time for any IF-based disease, the presence of the mutant protein in the characteristic histopathological feature of the disease, namely Rosenthal fibers. Collectively, these data confirm that the effects of the R416W GFAP are dominant, changing the assembly process in a way that encourages aberrant filament-filament interactions that then lead to protein aggregation and chaperone sequestration as early events in Alexander disease.

Glial fibrillary acidic protein (GFAP) is an intermediate filament protein found predominantly in astrocytes. This specificity has recommended the GFAP gene promoter for targeting transgene expression to astrocytes. Although both we [Brenner et al. J. Neurosci. 14:1030-1037, (1994)] and others [Mucke et al. New Biol. 3:465-474, (1991)] have reported astrocyte specificity for GFAP promoters, we demonstrate here that these DNA sequences can also direct activity in neurons. The pattern of neuronal activity varied with both the nature of the expressed sequence and the transgene insertion site. Specifically, neuronal expression was very high for a protective protein/cathepsin A minigene, moderate for lacZ and undetectable for GFP. These findings, coupled with a survey of the literature, recommend that investigators using GFAP-driven transgenes verify specificity for each line studied, using a detection system whose sensitivity is sufficient to detect a compromising level of misexpression.

Glial fibrillary acidic protein (GFAP) is an intermediate filament protein present primarily in astrocytes. The gene is first expressed as astrocytes mature, and in the adult is strongly upregulated in response to CNS damage. Thus, in addition to its astrocyte specificity, transcriptional regulation of the GFAP gene is of interest as a reporter of CNS signaling during development and injury. Several laboratories have shown that approximately 2 kb of 5'-flanking DNA of the human or mouse GFAP gene is sufficient to direct transgene expression to astrocytes and to confer developmental and injury-induced regulation. Enhancer regions have been identified adjacent to the basal promoter and about 1500 bp upstream of the RNA start site. Juxtaposition of these two segments yielded a 447 bp promoter, gfa28, which strongly drove reporter activity in transfected glioma cells. We report here that in mice a gfa28-lacZ transgene expresses in only certain brain regions, revealing an unexpected heterogeneity among astrocytes. The restricted pattern of expression is present early in development, is not altered by injury, and is preserved in cultured astrocytes. However, astrocytes cultured from an inactive region strongly express a transiently transfected gfa28-lacZ construct, and activity of the embedded gfa28-lacZ transgene is partially restored by treatment with a histone deacetylase inhibitor. These results indicate that the absence of gfa28-lacZ expression in specific brain regions results from a developmental failure to remodel GFAP chromatin to an open structure. Thus, expression of the gfa28-lacZ transgene appears to serendipitously mark a distinct set of astrocyte precursors.

No abstract

This paper presents a new white blood cell classification system for the recognition of five types of white blood cells. We propose a new segmentation algorithm for the segmentation of white blood cells from smear images. The core idea of the proposed segmentation algorithm is to find a discriminating region of white blood cells on the HSI color space. Pixels with color lying in the discriminating region described by an ellipsoidal region will be regarded as the nucleus and granule of cytoplasm of a white blood cell. Then, through a further morphological process, we can segment a white blood cell from a smear image. Three kinds of features (i.e., geometrical features, color features, and LDP-based texture features) are extracted from the segmented cell. These features are fed into three different kinds of neural networks to recognize the types of the white blood cells. To test the effectiveness of the proposed white blood cell classification system, a total of 450 white blood cells images were used. The highest overall correct recognition rate could reach 99.11% correct. Simulation results showed that the proposed white blood cell classification system was very competitive to some existing systems.

The ability to direct transgene expression to astrocytes has become increasingly important as the roles for these cells continue to expand. Promoters consisting of the 5'-flanking region of the human or mouse glial fibrillary acidic protein (GFAP) gene have generally proved satisfactory. However, a more powerful promoter would be advantageous for several applications, such as expression of dominant negative RNAs or proteins, or for gene therapy. We investigated the possibility of increasing the transcriptional activity of the human GFAP promoter by inserting into it one or three additional copies of putative GFAP enhancer regions. The promoters enhanced with three additional copies gave 75-fold higher LacZ expression levels upon plasmid transfection into GFAP-expressing U251 cells than the parental gfa2 promoter. Surprisingly, in a transgenic mouse model, the enhanced promoters resulted in no or only very low expression of marker genes, probably caused by toxicity. When various cell lines were infected with replication-deficient adenoviral vectors, the enhanced promoters gave LacZ expression levels that were approximately 10-fold higher than those with the parental gfa2 promoter, while retaining specificity for GFAP-expressing cells. Injection of the adenoviral vectors carrying the enhanced promoters into nude mouse brain showed that LacZ expression was limited to GFAP-positive cells. We conclude that gfa2 enhanced promoters are useful for production of short-term, glia-specific, high expression levels of genes in an adenoviral context. Adenoviral vectors containing these enhanced promoters may be useful in glioma gene therapy.

Virtual reality vestibular rehabilitation may be useful in patients with Ménière's disease, particular those in the early stages or having mild functional disability. Implication for rehabilitation Chronic imbalance caused by uncompensated Ménière's disease is an indication for vestibular rehabilitation. The interactive virtual reality video game, when integrated into vestibular rehabilitation exercise protocol, may assist patients who have mild disability Ménière's disease and who cannot benefit from treatment with drugs or surgery. The initial data from this study support the applicability of three-dimensional virtual reality technology in vestibular rehabilitation programs. The technology gives professionals a new tool to guide patients for vestibular rehabilitation exercises through three-dimensional virtual reality video game playing. The virtual reality vestibular exercise game can provide patients a step-wise, interactive, dynamic, three-dimensional, and interesting rehabilitation environment.